

Oncology Today with Dr Neil Love: Current and Future Management of  
Extrapulmonary Neuroendocrine Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following drug types best reflects the mechanism of action of obixtamig?
  - a. Proteasome inhibitor
  - b. Anti-PD-1 monoclonal antibody
  - c. PD-1 x LAG-3 bispecific antibody
  - d. DLL3 x CD3 bispecific antibody**
  - e. PD-L1 x CD137 bispecific antibody
  - f. XPO1 inhibitor
  - g. KRAS G12D inhibitor
2. In a Phase I study of obixtamig for patients with extrapulmonary neuroendocrine carcinoma, what was the approximate ORR (objective response rate) in the DLL3-high cohort?
  - a. 0%
  - b. 15%
  - c. 40%**
  - d. 70%
  - e. 100%
3. In the same Phase I study of obixtamig for patients with extrapulmonary neuroendocrine carcinoma, which of the following observations regarding cytokine release syndrome (CRS) was reported?
  - a. CRS was uncommonly observed
  - b. CRS was observed frequently, but most events were low grade**
  - c. CRS was observed frequently, and more than half the events were Grade  $\geq 3$
4. In the same Phase I study of obixtamig for patients with extrapulmonary neuroendocrine carcinoma, what was observed regarding duration of response by DLL3 expression level?
  - a. Patients with low levels of DLL3 expression had durable responses (eg, approximately 8 months)
  - b. Patients with high levels of DLL3 expression had durable responses (eg, approximately 8 months)**
  - c. Responses were short with obixtamig (eg, less than 4 months), regardless of DLL3 expression level
  - d. Responses were durable with obixtamig (eg, approximately 8 months), regardless of DLL3 expression level
5. Which of the following drug types best reflects the mechanism of action of LBL-024?
  - a. Proteasome inhibitor
  - b. Anti-PD-1 monoclonal antibody
  - c. PD-1 x LAG-3 bispecific antibody
  - d. DLL3 x CD3 bispecific antibody
  - e. PD-L1 x CD137 bispecific antibody**
  - f. XPO1 inhibitor
  - g. KRAS G12D inhibitor